Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer
Rodney P. Rocconi, Bradley J. Monk, Adam Walter, Thomas J. Herzog, Evanthia Galanis, Luisa Manning, Ernest Bognar, Gladice Wallraven, Laura Stanbery, Phylicia Aaron, Neil Senzer, Robert L. Coleman, John Nemunaitis
Topics & Concepts
MedicineVigilOvarian cancerHomologous recombinationHomologous chromosomeImmunotherapyCancer researchCancerOncologyInternal medicineGeneGeneticsBiologyHistoryArchaeologyPARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment